Aldeyra Therapeutics (ALDX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.70, -5.01% vs the prior close of $0.74.
- Volume 1.81M shares, 1.5x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ALDX slides 5.0% to $0.70, a 52-week low, 7 down days in a row. Closed at $0.70, -5.01% vs the prior close of $0.74. Day range $0.65–$0.74, opened at $0.74.
ALDX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ALDX slides 5.0% to $0.70, a 52-week low, 7 down days in a row
- Closed at $0.70, -5.01% vs the prior close of $0.74. Day range $0.65–$0.74, opened at $0.74.
- Volume was 1.81M shares, 1.5x its 50-day average of 1.22M.
- Price is -47.0% vs its 50-day average ($1.32) and -71.6% vs its 200-day average ($2.46).
- 52-week range $0.65–$5.93; today's close sits at 1% of that range, 88.2% below the 52-week high.
- That makes 7 straight losses.
Oct 15, 2026 — ALDX slides 6.7% to $0.74, a 52-week low, 6 down days in a row
- Closed at $0.74, -6.71% vs the prior close of $0.79. Day range $0.73–$0.80, opened at $0.77.
- Volume was 1.14M shares, 0.9x its 50-day average of 1.21M.
- Price is -44.9% vs its 50-day average ($1.34) and -70.3% vs its 200-day average ($2.48).
- 52-week range $0.73–$5.93; today's close sits at 0% of that range, 87.6% below the 52-week high.
- That makes 6 straight losses.
Oct 14, 2026 — ALDX slides 12.2% to $0.79, a 52-week low, 5 down days in a row
- Closed at $0.79, -12.22% vs the prior close of $0.90. Day range $0.79–$0.90, opened at $0.88.
- Volume was 1.58M shares, 1.3x its 50-day average of 1.20M.
- Price is -41.7% vs its 50-day average ($1.36) and -68.5% vs its 200-day average ($2.51).
- 52-week range $0.79–$5.93; today's close sits at 0% of that range, 86.7% below the 52-week high.
- That makes 5 straight losses.
Oct 13, 2026 — ALDX dips 0.7% to $0.90, a 52-week low, 4 down days in a row
- Closed at $0.90, -0.66% vs the prior close of $0.91. Day range $0.87–$0.91, opened at $0.89.
- Volume was 1.46M shares, 1.2x its 50-day average of 1.19M.
- Price is -34.4% vs its 50-day average ($1.37) and -64.4% vs its 200-day average ($2.53).
- 52-week range $0.86–$5.93; today's close sits at 1% of that range, 84.8% below the 52-week high.
- That makes 4 straight losses.
Oct 12, 2026 — ALDX dips 1.1% to $0.91, a 52-week low, 3 down days in a row
- Closed at $0.91, -1.09% vs the prior close of $0.92. Day range $0.88–$0.94, opened at $0.92.
- Volume was 1.34M shares, 1.1x its 50-day average of 1.17M.
- Price is -34.5% vs its 50-day average ($1.38) and -64.5% vs its 200-day average ($2.55).
- 52-week range $0.86–$5.93; today's close sits at 1% of that range, 84.7% below the 52-week high.
- That makes 3 straight losses.
Oct 9, 2026 — ALDX slides 3.4% to $0.92
- Closed at $0.92, -3.38% vs the prior close of $0.95. Day range $0.92–$0.97, opened at $0.94.
- Volume was 699.00K shares, 0.6x its 50-day average of 1.17M — lighter than usual.
- Price is -34.4% vs its 50-day average ($1.40) and -64.4% vs its 200-day average ($2.57).
- 52-week range $0.86–$5.93; today's close sits at 1% of that range, 84.6% below the 52-week high.
Oct 8, 2026 — ALDX dips 1.1% to $0.95
- Closed at $0.95, -1.15% vs the prior close of $0.96. Day range $0.91–$0.97, opened at $0.96.
- Volume was 1.18M shares, 1.0x its 50-day average of 1.16M.
- Price is -32.8% vs its 50-day average ($1.41) and -63.5% vs its 200-day average ($2.59).
- 52-week range $0.86–$5.93; today's close sits at 2% of that range, 84.0% below the 52-week high.
Oct 7, 2026 — ALDX jumps 4.7% to $0.96
- Closed at $0.96, +4.69% vs the prior close of $0.92. Day range $0.88–$0.97, opened at $0.91.
- Volume was 1.29M shares, 1.1x its 50-day average of 1.15M.
- Price is -32.6% vs its 50-day average ($1.42) and -63.3% vs its 200-day average ($2.61).
- 52-week range $0.86–$5.93; today's close sits at 2% of that range, 83.8% below the 52-week high.
Oct 6, 2026 — ALDX dips 0.9% to $0.92, a 52-week low on 8.1x normal volume
- Closed at $0.92, -0.87% vs the prior close of $0.92. Day range $0.86–$0.99, opened at $0.95.
- Volume was 8.23M shares, 8.1x its 50-day average of 1.01M — unusually heavy trading.
- Price is -36.2% vs its 50-day average ($1.44) and -65.2% vs its 200-day average ($2.63).
- 52-week range $0.86–$5.93; today's close sits at 1% of that range, 84.6% below the 52-week high.
- That makes 3 straight losses.
Oct 5, 2026 — ALDX slides 21.0% to $0.92, a 52-week low on 7.8x normal volume
- Closed at $0.92, -21.03% vs the prior close of $1.17. Day range $0.90–$1.18, opened at $1.18.
- Volume was 7.03M shares, 7.8x its 50-day average of 896.49K — unusually heavy trading.
- Price is -36.2% vs its 50-day average ($1.45) and -65.2% vs its 200-day average ($2.66).
- 52-week range $0.90–$5.93; today's close sits at 1% of that range, 84.4% below the 52-week high.
Oct 2, 2026 — ALDX slides 9.3% to $1.17 on 2.6x normal volume
- Closed at $1.17, -9.30% vs the prior close of $1.29. Day range $1.15–$1.31, opened at $1.31.
- Volume was 2.27M shares, 2.6x its 50-day average of 879.39K — unusually heavy trading.
- Price is -19.9% vs its 50-day average ($1.46) and -56.3% vs its 200-day average ($2.68).
- 52-week range $1.07–$5.93; today's close sits at 2% of that range, 80.3% below the 52-week high.
ALDX latest news & SEC filings
Every SEC filing by or about ALDX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 12, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$5.45M (prior year -$9.77M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.09 (prior year -$0.16) (loss narrowed vs Jun 30, 2025)
Jul 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Jul 27, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade ALDX
- Last results release: May 4, 2023 (8-K Item 2.02). Previous ones: Mar 9, 2023, Nov 10, 2022, Aug 5, 2022. Based on that rhythm, the next report is likely around Aug 3, 2023 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.67% (largest 21.0%). That is a volatile stock.
- Liquidity: about 2.02M shares (≈$1.42M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.70 vs a range of $0.65–$5.93 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 12 open-market buys, 0 sales; latest: Todd C Brady bought 250,000 shares on Jun 3, 2026.
- Latest filings: 8-K Sep 29, 2026; 10-Q Aug 6, 2026; 8-K Jul 30, 2026.
- Share count: 60.33M shares outstanding (Aug 4, 2026), +0.7% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ALDX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.74 | 0.74 | 0.65 | 0.70 | 1.81M |
| Oct 15, 2026 | 0.77 | 0.80 | 0.73 | 0.74 | 1.23M |
| Oct 14, 2026 | 0.88 | 0.90 | 0.79 | 0.79 | 1.58M |
| Oct 13, 2026 | 0.89 | 0.91 | 0.87 | 0.90 | 1.46M |
| Oct 12, 2026 | 0.92 | 0.94 | 0.88 | 0.91 | 1.34M |
| Oct 9, 2026 | 0.94 | 0.97 | 0.92 | 0.92 | 699.00K |
| Oct 8, 2026 | 0.96 | 0.97 | 0.91 | 0.95 | 1.18M |
| Oct 7, 2026 | 0.91 | 0.97 | 0.88 | 0.96 | 1.29M |
| Oct 6, 2026 | 0.95 | 0.99 | 0.86 | 0.92 | 8.23M |
| Oct 5, 2026 | 1.18 | 1.18 | 0.90 | 0.92 | 7.03M |
| Oct 2, 2026 | 1.31 | 1.31 | 1.15 | 1.17 | 2.27M |
| Oct 1, 2026 | 1.26 | 1.30 | 1.20 | 1.29 | 1.21M |
| Sep 30, 2026 | 1.34 | 1.35 | 1.22 | 1.23 | 1.65M |
| Sep 29, 2026 | 1.17 | 1.44 | 1.16 | 1.32 | 5.45M |
| Sep 28, 2026 | 1.18 | 1.22 | 1.15 | 1.16 | 1.02M |
| Sep 25, 2026 | 1.23 | 1.28 | 1.20 | 1.21 | 644.70K |
| Sep 24, 2026 | 1.35 | 1.35 | 1.22 | 1.22 | 835.10K |
| Sep 23, 2026 | 1.40 | 1.40 | 1.33 | 1.35 | 630.10K |
| Sep 22, 2026 | 1.37 | 1.40 | 1.35 | 1.39 | 428.60K |
| Sep 21, 2026 | 1.37 | 1.39 | 1.32 | 1.35 | 494.80K |
About Aldeyra Therapeutics
Aldeyra Therapeutics (ALDX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CONCORD, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1341235.
ALDX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Todd C Brady | President and CEO | Jun 5, 2026 |
| Ben Bronstein | Director | Jun 11, 2026 |
| William D Clark | Director | Jun 11, 2026 |
| Darlene M Deptula-Hicks | Director | Jun 11, 2026 |
| Richard Douglas | Director | Jun 11, 2026 |
| Nancy Miller-Rich | Director | Jun 11, 2026 |
| Gary M. Phillips | Director | Jun 11, 2026 |
| Neal Walker | Director | Jun 11, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Michael Alfieri | Principal Financial Officer | Mar 19, 2026 |
| Todd C Brady | President and CEO | Jun 5, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 3, 2026 | Todd C Brady | Buy | 250,000 | $1.67 |
| Jun 3, 2026 | Todd C Brady | Buy | 250,000 | $1.67 |
| Jun 3, 2026 | Todd C Brady | Buy | 250,000 | $1.67 |
| Jun 3, 2026 | Todd C Brady | Buy | 250,000 | $1.67 |
| Mar 19, 2026 | Richard Douglas | Buy | 70,000 | $1.40 |
| Mar 19, 2026 | Richard Douglas | Buy | 70,000 | $1.40 |
| Mar 19, 2026 | Richard Douglas | Buy | 70,000 | $1.40 |
| Mar 19, 2026 | Richard Douglas | Buy | 70,000 | $1.40 |
| Mar 18, 2026 | Michael Alfieri | Buy | 5,000 | $1.42 |
| Mar 18, 2026 | Michael Alfieri | Buy | 5,000 | $1.42 |
| Mar 18, 2026 | Michael Alfieri | Buy | 5,000 | $1.42 |
| Mar 18, 2026 | Michael Alfieri | Buy | 5,000 | $1.42 |
ALDX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-33.85M | -0.56 | $-33.35M |
| Dec 31, 2024 | — | $-55.85M | -0.94 | $-43.21M |
| Dec 31, 2023 | — | $-37.54M | -0.64 | $-30.33M |
| Dec 31, 2022 | — | $-62.02M | -1.06 | $-56.64M |
| Dec 31, 2021 | — | $-57.78M | -1.07 | $-42.56M |
Latest balance sheet: total assets $47.54M, total liabilities $9.66M, cash $70.04M (as of Jun 30, 2026).
ALDX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| May 4, 2023 | 8-K Item 2.02 (results) | — |
| Mar 9, 2023 | 8-K Item 2.02 (results) | — |
| Nov 10, 2022 | 8-K Item 2.02 (results) | — |
| Aug 5, 2022 | 8-K Item 2.02 (results) | — |
| May 5, 2022 | 8-K Item 2.02 (results) | — |
| Mar 17, 2022 | 8-K Item 2.02 (results) | — |
| Oct 28, 2021 | 8-K Item 2.02 (results) | — |
| Aug 5, 2021 | 8-K Item 2.02 (results) | — |
| May 6, 2021 | 8-K Item 2.02 (results) | — |
| Mar 11, 2021 | 8-K Item 2.02 (results) | — |
| Nov 5, 2020 | 8-K Item 2.02 (results) | — |
| Aug 6, 2020 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ALDX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.